Live Breaking News & Updates on Ascendis Pharma Group|Page 5

Stay updated with breaking news from Ascendis pharma group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial ...

Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

New York , United States , New Jersey , Palo Alto , Redwood City , Baden Wüberg , South Korea , Ascendis Pharma , Mishaela Rubin , Mark Bach , Endocrine Society , Ascendis Pharma Group , European Commission , Drug Administration , Ascendis Pharma Hp Patient Experience Research , Endocrine Medical Sciences At Ascendis Pharma , Exchange Commission , Associate Professor , Metabolic Bone Disease Unit , Vagelos College , Columbia University Irving Medical Center , Hypoparathyroidism Patient Experience Scale , Data Highlights , Hormone Replacement Therapy , Month Update , Open Label Extension ,

Ascendis Pharma A/S Reports Full Year 2020 Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ascendis Pharma A/S Reports Full Year 2020 Financial Results
Ascendis PharmaMarch 10, 2021 GMT
– Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track –
– Oncology pipeline advancing into clinical trials beginning with TransCon TLR7/8 Agonist –
–
–
COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced financial results for the full year ended December 31, 2020.
ADVERTISEMENT
“2020 was a year to remember for Ascendis as our global workforce delivered on time or ahead of schedule on all of our corporate milestones, advancing Vision 3x3, the company’s strateg ....

United States , New Jersey , Palo Alto , Redwood City , Baden Wuberg , Jan Mikkelsen , Ascendis Pharma , Ascendis Pharma Group , European Commission , Drug Administration , Dial In International , Exchange Commission , Company Highlights Progress , Visen Pharmaceuticals , European Medicines Agency , Endocrinology Rare Disease , Ascendi President , Submitted Clinical Trial Notification , North America , Greater China , European Medicines , Biologics License Application , Annual Report , Tim Lee , Products And Services , Earnings Conference Calls ,